Sites are often advised on things they can do to improve the payment process on their end, but sponsors can also take action to make sites’ financial situations significantly less stressful, according to one sponsor representative.
With recent data driving home the challenges faced on enrollment, staffing and protocol complexity this year, sites are saying they want to know what to expect from sponsors on a range of items, including timelines, feasibility, training and technology, among others. Read More
Evidence generation has undeniably grown beyond traditional trials to include a number of other sources and continues to evolve. Amy Abernethy, former FDA deputy chief, sees a future in which therapies are approved earlier and continually evaluated with high-quality data, but it will be on industry to connect the dots and build a strong foundation to make this a reality, she says. Read More
When clinical trial stakeholders meet, a major focus of discussion is the concept of collaboration and the industry’s inefficiency in adopting innovations. Read More
Regardless of size, sites can implement many patient-centric changes without significant costs, and inexpensive ones can actually have a very positive impact, according to DM Clinical, a U.S. site network that’s earned praise for its lower-cost, data-driven approach to putting patients first. Read More
Industry stakeholders are pessimistic about the state of the CRA workforce and don’t believe progress has been made in combatting shortages, underscoring the need for innovation in how CRAs are trained and evaluated, according to a recent survey.
Clinical research has seen marked upheaval in just a few short years as traditional methods were rethought and innovative changes enacted. In 2023, the industry can expect significant progress in the use of artificial intelligence (AI), decentralized and hybrid trials, and site-enabling solutions, as well as further efforts to combat ongoing recruitment and workforce challenges. The CenterWatch Monthly polled a variety of experts on these and other topics. Here’s what they had to say. Read More
FDA Commissioner Robert Califf has called for major reform of the clinical research enterprise, particularly in how clinical evidence is gathered, to reduce health disparities between scientific advancement and actual U.S. life expectancy, a huge undertaking that some clinical trial experts question. Read More
Time and effort have their own value and should be budgeted and billed for just as more tangible costs — tests, patient visits, trial supplies, etc. — are, say budgeting and contracting experts who warn sites about letting these intangibles slip through cracks in their systems. Read More
Sponsor and CRO acceptance of site input drives site satisfaction, according to a new study that shows sites are three or four times more likely to have a positive view of clinical trials’ future if their sponsors/CROs are open to feedback. But most still have concerns they would like to have addressed. Read More